

CELGENE CORP /DE/  
Form 8-K  
June 28, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 28, 2018**

**CELGENE CORPORATION**

**(Exact name of registrant as specified in its charter)**



Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. “

**ITEM 8.01**

**OTHER EVENTS**

On June 28, 2018, Celgene Corporation announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo.

Attached hereto and incorporated by reference as Exhibit 99.1 is the Press Release announcement.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

Exhibit 99.1 – Press Release dated June 28, 2018

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: June 28, 2018    By: /s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President and Chief Financial Officer  
  
(principal financial and accounting officer)